Guo ZG, Han Z, Yuan HM. Pretreatment with gabexate mesilate alters expression of vasoactive intestinal peptide and neuronal nitric oxide synthase in the duodenal mucosa of patients undergoing ERCP.
Shijie Huaren Xiaohua Zazhi 2011;
19:1731-1734. [DOI:
10.11569/wcjd.v19.i16.1731]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To explore the effect of pretreatment with gabexate mesilate on the expression of vasoactive intestinal peptide (VIP) and neuronal nitric oxide synthase (nNOS) in the duodenal mucosa of patients undergoing endoscopic retrograde cholangiopancreatography (ERCP).
METHODS: A total of thirty patients with unexplained abdominal pain and jaundice were recruited to the study from September 2009 to July 2010 and divided into two groups: patients intravenously infused with gabexate mesilate and those with saline before ERCP. Three minutes after infusion, specimens were taken to detect the levels of VIP and nNOS by means of double-antibody sandwich ELISA.
RESULTS: The level of VIP (ng/L) in the papillary mucosa of patients pretreated with gabexate mesilate was significantly higher than that of controls (0.032 ± 0.004 vs 0.031 ± 0.002, P < 0.05), while that of nNOS showed no statistical difference between the two groups of patients. The mean content of nNOS (μmol/L) in the sphincter of Oddi of patients pretreated with gabexate mesilate was significantly higher than that of controls (9.55 ± 1.10 vs 8.29 ± 0.56, P < 0.01), while there was no marked difference in the level of nNOS in the sphincter of Oddi between the two groups of patients.
CONCLUSION: Pretreatment with gabexate mesilate up-regulates the expression of VIP in the papillary mucosa and nNOS in the sphincter of Oddi in patients undergoing ERCP.
Collapse